Meniere Disease - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Meniere Disease - Pipeline Review, H2 2016

Meniere Disease - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Meniere Disease - Pipeline Review, H2 2016
Published Aug 17, 2016
48 pages — Published Aug 17, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Meniere Disease - Pipeline Review, H2 2016, provides an overview of the Meniere Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Meniere Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Meniere Disease and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Meniere Disease
- The report reviews pipeline therapeutics for Meniere Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Meniere Disease therapeutics and enlists all their major and minor projects
- The report assesses Meniere Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Meniere Disease

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Meniere Disease
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Meniere Disease pipeline depth and focus of Indication therapeutics
-

  
Source:
Document ID
GMDHC8357IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Meniere Disease Overview61
Therapeutics Development71
  Pipeline Products for Meniere Disease Overview71
Meniere Disease Therapeutics under Development by Companies81
Meniere Disease Pipeline Products Glance94
  Late Stage Products91
  Clinical Stage Products101
  Early Stage Products111
  Unknown Stage Products121
Meniere Disease Products under Development by Companies131
Meniere Disease Companies Involved in Therapeutics Development145
  Orbis Biosciences Inc141
  Otonomy, Inc.151
  Quark Pharmaceuticals, Inc.161
  Sound Pharmaceuticals, Inc.171
  Synphora AB181
Meniere Disease Therapeutics Assessment199
  Assessment by Monotherapy Products191
  Assessment by Target202
  Assessment by Mechanism of Action222
  Assessment by Route of Administration242
  Assessment by Molecule Type262
Drug Profiles2810
  betamethasone valerate ER Drug Profile281
  dexamethasone acetate SR Drug Profile294
  latanoprost Drug Profile331
  OR-105 Drug Profile341
  QPHL-2 Drug Profile351
  SPI-1005 Drug Profile362
Meniere Disease Dormant Projects381
Meniere Disease Product Development Milestones398
  Featured News &Press Releases391
    Aug 01, 2016: Otonomy Successfully Completes One-Year, Multiple-Dose Clinical Safety Trial for OTO-104 in Meniere Disease Patients391
    Mar 23, 2016: Otonomy Initiates Patient Enrollment in Second Phase 3 Clinical Trial of OTO-104 in M ni re s Disease391
    Jan 26, 2016: Otonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss401
    Nov 18, 2015: Otonomy Initiates Patient Enrollment in U.S. Phase 3 Clinical Trial of OTO-104 in Meniere Disease401
    Sep 24, 2015: Otonomy to Present Results for OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting411
    Sep 09, 2015: Otonomy Announces Successful End-of-Phase 2 Meeting With the FDA for OTO-104 in Meniere Disease411
    May 21, 2015: Otonomy Reports Phase 2b Topline Data for OTO-104 in Meniere Disease411
    Apr 20, 2015: Otonomy Completes Enrollment of OTO-104 Multiple-Dose Safety Study in Meniere Disease Patients421
    Dec 01, 2014: Otonomy Achieves Patient Enrollment Target in Phase 2b Clinical Trial of OTO-104 in Meniere Disease431
    Oct 09, 2014: Otonomy Enrolls First Meniere Disease Patients in OTO-104 Multiple-Dose Safety Study431
    Dec 11, 2013: Otonomy Enrolls First Patient in Pivotal Phase 2b Study of OTO-104 in Meniere Disease431
    Sep 29, 2011: Otonomy Presents Positive New Findings From Phase Ib Study Of OTO-104 In Meniere Disease At International Conference441
    Apr 28, 2011: Otonomy Announces Positive Results From Phase Ib Study Of OTO-104 In M ni re s Disease452
Appendix472
  Methodology471
  Coverage471
  Secondary Research471
  Primary Research471
  Expert Panel Validation471
  Contact Us471
  Disclaimer481

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Meniere Disease - Pipeline Review, H2 2016" Aug 17, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Meniere-Disease-Pipeline-Review-H2-2016-2088-16384>
  
APA:
Global Markets Direct - Market Research. (2016). Meniere Disease - Pipeline Review, H2 2016 Aug 17, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Meniere-Disease-Pipeline-Review-H2-2016-2088-16384>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.